Insilico Medicine Announces Industrys First Longevity Board to Accelerate AIDriven Aging Research for Drug Discovery

Image for article Insilico Medicine Announces Industrys First Longevity Board to Accelerate AIDriven Aging Research for Drug Discovery
News Source : Associated Press

News Summary

  • Insilico Medicine announces formation of industry’s first Longevity Board (Board) Board provides scientific oversight and strategic guidance for AI-enabled aging research and drug discovery.
  • Board will oversee work in life models, biomarkers of aging, identification of dual-purpose targets implicated in aging, longevity and disease, and clinical development.
  • Board is composed of high-profile scientists involved in aging and disease research including Dr. Andrew Adams, Group Vice President of Molecular Discovery at Lilly.
  • Dr. Adams’ deep expertise in genetic medicine design and large-scale R&D operations will provide Insilico with the “Big Pharma” perspective necessary to transition experimental longevity compounds into commercially viable medicines.
CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ Insilico Medicine (Insilico, 3696.HK), a clinicalstage generative artificial intelligence (AI)driven biotechnology company, today announced the stra [+6119 chars]

Must read Articles